Publications

Bhattacharyya S, Zagórska A, Lew ED, Shrestha B, Rothlin CV, Naughton J, Diamond MS, Lemke G and Young JA: Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe. 2013 Aug 14;14 (2) :136-47. PMID: 23954153


Bosurgi L, Bernink JH, Delgado Cuevas V, Gagliani N, Joannas L, Schmid ET, Booth CJ, Ghosh S and Rothlin CV: Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A. 2013 Aug 6;110 (32) :13091-6. Epub 2013 Jul 22. PMID: 23878224


Carrera Silva EA, Chan PY, Joannas L, Errasti AE, Gagliani N, Bosurgi L, Jabbour M, Perry A, Smith-Chakmakova F, Mucida D, Cheroutre H, Burstyn-Cohen T, Leighton JA, Lemke G, Ghosh S and Rothlin CV: T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity. 2013 Jul 25;39 (1) :160-70. Epub 2013 Jul 11. PMID: 23850380


van den Brand BT, Abdollahi-Roodsaz S, Vermeij EA, Bennink MB, Arntz OJ, Rothlin CV, van den Berg WB and van de Loo FA: Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis. Arthritis Rheum. 2013 Mar;65 (3) :671-80. PMID: 23203851

Rothlin CV and Lemke G: TAM receptor signaling and autoimmune disease. Curr Opin Immunol. 2010 Dec;22 (6) :740-6. Epub 2010 Oct 26. PMID: 21030229

Lemke G and Rothlin CV: Immunobiology of the TAM receptors. Nat Rev Immunol. 2008 May;8 (5) :327-36. PMID: 18421305

Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB and Lemke G: TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007 Dec 14;131 (6) :1124-36. PMID: 18083102


Roth C, Rothlin C, Riou S, Raulet DH and Lemke G: Stromal-cell regulation of natural killer cell differentiation. J Mol Med (Berl). 2007 Oct;85 (10) :1047-56. Epub 2007 Apr 11. PMID: 17426948

Ghosh S, Tergaonkar V, Rothlin CV, Correa RG, Bottero V, Bist P, Verma IM and Hunter T: Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell. 2006 Sep;10 (3) :215-26. PMID: 16959613


Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P and Lemke G: TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci. 2006 Sep;33 (1) :96-108. Epub 2006 Aug 9. PMID: 16901715


Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN and Ivashkiv LB: Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med. 2006 Aug 7;203 (8) :1891-901. Epub 2006 Jul 10. PMID: 16831897

Ballestero JA, Plazas PV, Kracun S, Gómez-Casati ME, Taranda J, Rothlin CV, Katz E, Millar NS and Elgoyhen AB: Effects of quinine, quinidine, and chloroquine on alpha9alpha10 nicotinic cholinergic receptors. Mol Pharmacol. 2005 Sep;68 (3) :822-9. Epub 2005 Jun 13. PMID: 15955868

Rothlin CV, Lioudyno MI, Silbering AF, Plazas PV, Casati ME, Katz E, Guth PS and Elgoyhen AB: Direct interaction of serotonin type 3 receptor ligands with recombinant and native alpha 9 alpha 10-containing nicotinic cholinergic receptors. Mol Pharmacol. 2003 May;63 (5) :1067-74. PMID: 12695535

Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF and Boulter J: alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci U S A. 2001 Mar 13;98 (6) :3501-6. Epub 2001 Mar 6. PMID: 11248107

Rothlin CV, Katz E, Verbitsky M, Vetter DE, Heinemann SF and Elgoyhen AB: Block of the alpha9 nicotinic receptor by ototoxic aminoglycosides. Neuropharmacology. 2000 Oct;39 (13) :2525-32. PMID: 11044724


Verbitsky M, Rothlin CV, Katz E and Elgoyhen AB: Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor. Neuropharmacology. 2000 Oct;39 (13) :2515-24. PMID: 11044723


Katz E, Verbitsky M, Rothlin CV, Vetter DE, Heinemann SF and Elgoyhen AB: High calcium permeability and calcium block of the alpha9 nicotinic acetylcholine receptor. Hear Res. 2000 Mar;141 (1-2) :117-28. PMID: 10713500